Background The original non–vitamin K antagonist oral anticoagulant (NOAC) trials in
nonvalvular atrial fibrillation (AF) enrolled patients with native valve pathologies. The object …

Background: Valvular heart disease (VHD) and atrial fibrillation (AF) often coexist. Phase III
trials comparing non–vitamin K antagonist oral anticoagulants (NOACs) with warfarin …

Background Non-vitamin K antagonist (VKA) oral anticoagulants (NOACs) are widely used
as stroke prophylaxis in non-valvular atrial fibrillation (AF), but comparative data are sparse …

Background Stroke is the most serious clinical consequence of atrial fibrillation, which is the
most common cardiac arrhythmia. Non-vitamin K antagonist oral anticoagulants (NOACs) …

Objective Current guidelines endorse the use of non-vitamin K antagonist oral
anticoagulants (NOACs) in patients with atrial fibrillation (AF). However, little is known about …

Purpose The findings from the observational studies comparing the effectiveness and safety
of non–vitamin K antagonist oral anticoagulants (NOACs) versus vitamin K antagonists …

The non-vitamin K antagonist oral anticoagulants (NOACs) have been increasingly
prescribed in clinical practice for stroke prevention in patients with nonvalvular atrial …

Objective Non-vitamin K antagonist oral anticoagulants (NOACs) are efficacious and safe
antithrombotic drugs but the non-availability of an antidote for potential fatal haemorrhagic …

Aims The well-known limitations of vitamin K antagonists (VKA) led to development of new
oral anticoagulants (NOAC) in non-valvular atrial fibrillation (NVAF). The aim of this meta …

Background Non-vitamin K antagonist oral anticoagulants (NOACs) are at least as effective
and safe as vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF). All …